Celcuity needs facility sign-off to kick off its market launch
Latest Fierce Pharma coverage of Celcuity needs facility sign-off to kick off its market launch
Celcuity
Private
PI3K/mTOR therapies, Companion Diagnostics
Company Info
Recent News
Celcuity awaits FDA review for second factory to launch cancer drug
Endpoints News reports Celcuity is awaiting FDA review of a second manufacturing facility to support commercial launch of its cancer drug.
Celcuity gains FDA approval for closely watched breast cancer drug
Celcuity gains FDA approval for the closely watched breast cancer drug Revtorpyk (gedatolisib).
Celcuity wins breast cancer nod, securing ‘differentiated foothold’ in market
Celcuity wins breast cancer nod, securing ‘differentiated foothold’ in market
Celcuity set to be Big Pharma 'strategic target' after approval
Celcuity set to be Big Pharma 'strategic target' after approval
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer